NICE guidance published today recommends leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...

NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 5 sources, ...

Hypertension is a major risk factor for cardiovascular and chronic kidney diseases. Hypertension can be primary or secondary. Primary hypertension does not have a single known cause, but secondary ...

This procedure can only be done as part of a research study. This is because there is not enough evidence to be sure how well it works or how safe it is. Your healthcare professional should talk to ...

More research is needed on alcohol-mediated perivascular renal sympathetic denervation for treating resistant hypertension before it can be used in the NHS.

This new manual sets out the foundations for the HealthTech programme following the first part of our transformation to be simpler, relevant and purpose-led. It is the first step in an ongoing ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...